Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Expects fourth quarter and full year 2025 Recorlev ® net revenue of $45 million and $139 million, respectively Full-year 2025 financial results and 2026 outlook planned for March 2, 2026 CHICAGO, January 08, 2026 BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our fourth quarter performance capped off a truly transformative 2025. Recorlev ® delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year," said John Shannon, Chief Executive Officer. "When combined with the stellar contributions of Gvoke ® and Keveyis ® , we expect total revenue of approximately $292 million, exceeding the high end of our full-year 2025 guidance." Shannon continued, "As we look ahead, we are incredibly excited about the opportunities before us. We enter the year with strong commercial moment
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]Yahoo! Finance
- Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total RevenueBusiness Wire
XERS
Earnings
- 11/6/25 - Miss
XERS
Sec Filings
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- 1/8/26 - Form 8-K
- XERS's page on the SEC website